Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

cancer, established triple positive antiphospholipid syndrome or extreme body weight (less than 50 kg or more than 120 kg): • offer continued treatment with the current anticoagulant if it is well tolerated or • if the current treatment is not well tolerated, or the clinical situation or person's preferences have changed, consider switching to apixaban if the current treatment is a direct-acting anticoagulant other than apixaban. [2020] 1.4.9 For people with renal impairment, active cancer, established triple positive antiphospholipid syndrome or extreme body weight (less than 50 kg or more than 120 kg), consider carrying on with the current treatment if it is well tolerated. [2020] 1.4.10 If anticoagulation treatment fails follow the recommendation on treatment failure. [2020] 1.4.11 For people who decline continued anticoagulation treatment, consider aspirin 75 mg or 150 mg daily. In March 2020, the use of aspirin for secondary prevention of DVT or PE was off label. See NICE's information on prescribing medicines. [2020] 1.4.12 Review general health, risk of VTE recurrence, bleeding risk and treatment preferences at least once a year for people taking long-term anticoagulation treatment or aspirin. [2020] For a short explanation of why the committee made the 2020 recommendations on reviewing anticoagulation
